BridgeMD
New treatment option for Cardiotoxicity
Official title NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity
ClinicalTrials.gov ID: NCT06340516
What this study is testing
- What it's testing
- Trastuzumab-induced cardiotoxicity (TIC) will be monitored in patients with HER2+ breast cancer undergoing trastuzumab treatment before and after breast cancer surgery. At baseline before start of trastuzumab treatment, echocardiography (ECHO)/multigated Acquisition Scan (MUGA) and measurement of plasma NT-proBNP will be performed.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histological confirmed HER2 positive primary BC planned for adjuvant/neoadjuvant treatment with chemotherapy plus HER2 blocking agents.
- Patients ≥18 years
- ECOG/WHO 0-1
- Adequate organ function for the planned treatment according to local guidelines.
- No distant metastasis (CT/MRI only if clinically indicated).
You likely can't join if
- Patients with previous heart disease recommended special follow-up during treatment with high risk of termination of treatment.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or...
- Pregnancy and breast feeding.
- Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ). \-
See the full eligibility criteria
- Histological confirmed HER2 positive primary BC planned for adjuvant/neoadjuvant treatment with chemotherapy plus HER2 blocking agents.
- Patients ≥18 years
- ECOG/WHO 0-1
- Adequate organ function for the planned treatment according to local guidelines.
- No distant metastasis (CT/MRI only if clinically indicated).
- Negative pregnancy test within 14 days prior to start of treatment.
- If of childbearing potential, willing to use an effective form of contraception.
- No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
- Signed informed consent and willingness to follow the trial procedures.
- Patients with previous heart disease recommended special follow-up during treatment with high risk of termination of treatment.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect...
- Pregnancy and breast feeding.
- Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ). \-
The study team makes the final eligibility decision.
Where it's taking place
- Gothenburg, Sweden
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Gothenburg, Sweden. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.